ClinicalTrials.gg

Pruritus clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 491 studies for Pruritus across more than 10 countries. 94 are recruiting or about to start. 256 of them are mainly about Pruritus (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13. Counting its narrower condition Tinea Pedis too: 562 studies, 101 open.

Status

Completed
304
Recruiting
54
Status unknown
36
Not yet recruiting
34
Terminated
31
Withdrawn
15

Phase

Phase 2
128
Phase 3
94
Phase 4
41
Phase 1
37
Early Phase 1
10

Where

United States
163
Germany
58
Canada
54
China
48
France
45
Poland
42

Who develops what

Add Pruritus to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 18 programs from 16 companies, 7 with this as their studies’ main aim; 6 with a live phase 3 study; 5 primary completions in the next 12 months. Compare Lunan Pharmaceutical Group, Arcutis Biotherapeutics and Bristol-Myers Squibb here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
EstradiolEarlier only
Evidence
  • NCT03332303 · prasco llc · Phase 3 · comparator · “Estrace® Cream” · registered Nov 2017
  • NCT02195986 · Viatris Inc. · Phase 3 · comparator · “Estrace® 0.01% cream” · registered Jul 2014
Novo Nordisk A/S17% of its industry studiesUS: off-patent, 37 generics marketed00 studies
calcipotrieneEarlier only
Evidence
  • NCT03448081 · Sienna Biopharmaceuticals · Phase 2 · background · “Calcipotriene” · registered Feb 2018
  • NCT00796211 · Zalicus · Phase 2 · comparator · “Calcipotriol” · registered Nov 2008
LEO Pharma56% of its industry studiesUS: off-patent, 6 generics marketed00 studies
DesonideEarlier only
Evidence
  • NCT02286700 · neostrata company inc · Phase 3 · comparator · “Desonide Cream” · registered Nov 2014
  • NCT01467362 · Pierre Fabre · Phase 3 · background · “desonide 0.1% cream” · registered Oct 2011
Dr. Reddy's Laboratories Limited100% of its industry studiesUS: off-patent, 10 generics marketed00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
linerixibatApproved: US 2026 · EU 2026☆ Track1 live phase-3 study: NCT07860710GlaxoSmithKline
remibrutinibApproved: US 2025 · EU 2026☆ Track2 live phase-3 studies: NCT07700056, NCT07811869Novartis

The 2 in phase 3 with the nearest primary completion, of 18 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (5)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.nemolizumab · Galderma Group AG · Phase 2 main aimNCT07074977 Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO) — primary endpoint: Population Pharmacokinetics (PopPK) Model of the Elimination of nemolizumab During the 16-week Treatment Period Point · 50 enrolled
  • 25 Dec 2026 est.ritlecitinib · Pfizer · Phase 2 registry mapping onlyNCT07219615 A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. — primary endpoint: Change from baseline in Urticaria Activity Score 7 (UAS7) at Week 12 · 200 enrolled
  • 1 Mar 2027 est.nalmefene · tharimmune inc · Phase 2 main aimNCT06733519 TH104 for the Treatment of Pruritus in Primary Biliary Cholangitis — primary endpoint: The primary objective is to investigate the safety and tolerability of repeat doses of TH104 · 40 enrolled

2 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Pruritus studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 5 open · JAK inhibitors 4 open · Antiemetics 1 open · NK1 receptor antagonists 1 open · Opioid antagonists 1 open

Coming up

37studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger. 15 (28%) take children under 18. 5 (9%) are for women only and 0 (0%) for men only; 10 (19%) take healthy volunteers.

Recruiting studies that take each age, of 54
AgeWomenMen
107 (13%)7 (13%)
1849 (91%)45 (83%)
3050 (93%)45 (83%)
4050 (93%)45 (83%)
5046 (85%)43 (80%)
6541 (76%)40 (74%)
7533 (61%)32 (59%)
8527 (50%)26 (48%)

Across all 491 studies, recruiting or not: 43% stop at 75 or younger and 32% at 65; 19% take children; 6% are for women only and 2% for men only; 21% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Pruritus studies take

Of 52 phase 2 interventional studies under Pruritus, half reached primary completion within 16 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 16 mo3–14 · 21 studies——
Phase 216 mo10–31 · 52 studies14 mo10–21 · 37 studies—
Phase 319 mo12–29 · 48 studies19 mo12–26 · 42 studies—
Phase 422 mo12–33 · 19 studies——
Interventional, no phase7 mo3–13 · 101 studies—7 mo4–14 · 85 studies
Observational12 mo5–35 · 21 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 491. Browse all 491 → or search them.